United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $259.60, for a total value of $2,076,800.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $33,748. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Up 0.6 %

Shares of NASDAQ UTHR opened at $261.70 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 9.39 and a current ratio of 9.68. The business's 50 day moving average price is $270.84 and its 200-day moving average price is $241.24. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $283.09. The company has a market cap of $11.93 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 1.55 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping the consensus estimate of $3.57 by $1.34. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. The firm had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. On average, sell-side analysts expect that United Therapeutics Co. will post 16.57 earnings per share for the current year.

Institutional Inflows and Outflows

Analysts Set New Price Targets

A number of research firms recently commented on UTHR. UBS Group began coverage on United Therapeutics in a research report on Tuesday, December 6th. They issued a "buy" rating and a $320.00 target price on the stock. The Goldman Sachs Group began coverage on United Therapeutics in a research report on Monday, December 5th. They issued a "sell" rating and a $230.00 target price on the stock. Argus boosted their target price on United Therapeutics from $250.00 to $300.00 and gave the stock a "buy" rating in a research report on Wednesday, January 11th. Wedbush boosted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. Finally, Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an "outperform" rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $283.64.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

• Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
• CVS Health is Growing into an Integrated Healthcare Organization
• Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
• NVIDIA Outlook Improving: Watchlist Candidate for 2023
• Which Wireless Stock Should You Buy in 2023?
• Is Virgin Galactic Stock Preparing for Lift-Off?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.